ABSTRACT
Background Anemia affects one in three pregnant women worldwide, with the greatest burden in South Asia and sub-Saharan Africa. During pregnancy, anemia has been linked to an increased risk of adverse maternal and neonatal health outcomes. Despite widespread recognition that anemia can complicate pregnancy, critical gaps persist in our understanding of the specific causes of maternal anemia and the cutoffs used to diagnose anemia in each trimester and in the postpartum period.
Methods and analysis The Redefining Maternal Anemia in Pregnancy and Postpartum (ReMAPP) study is a multisite, prospective, cohort study nested within the Pregnancy Risk, Infant Surveillance, and Measurement Alliance (PRISMA) Maternal and Newborn Health study. Research sites are located in Kenya, Ghana, Zambia, India, and Pakistan. Participants are up to 12,000 pregnant women who provide serial venous blood samples for hemoglobin assessment at five time points: at <20 weeks, 20 weeks, 28 weeks, and 36 weeks gestation and at six weeks postpartum. We will use two analytical approaches to estimate hemoglobin thresholds for defining anemia: (1) clinical decision limits for cutoffs in each trimester and at six weeks postpartum based on associations of hemoglobin levels with adverse maternal, fetal, and neonatal health outcomes and (2) reference limits for gestational-week-specific cutoffs and at six weeks postpartum for mild, moderate, and severe anemia based on tail statistical percentiles of hemoglobin values in a reference (i.e., clinically healthy) subpopulation. We will also conduct biomarker-intensive testing among a sub-sample of participants in each trimester to explore underlying contributing factors of maternal anemia.
Ethics and dissemination The study received local and national ethical approvals from all participating institutions. Findings from multisite analyses will be published among open-access, peer-reviewed journals and disseminated with local, national, and international partners.
Registration ClinicalTrials.gov (ID: PRISMA-MNH 2022; NCT05904145)
Strengths and limitations
Novel study design to allow multiple analytical approaches (clinical decision limits and reference limits) in the same population to establish hemoglobin thresholds.
Use of gold standard methods and external quality assurance programs to ensure harmonized hemoglobin measurement across sites.
Inclusion of biomarker-intensive study arm to examine the etiology of anemia among pregnant women.
All data is contributed by populations historically underrepresented in research in low- and middle-income countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol, the informed consent documents and any subsequent modifications will be reviewed and approved by the relevant institutional review board (IRB) and ethics review committee (ERC) responsible for oversight of the study at each site. IRB approvals for this research were received from the following ERCs in each country: Ghana (Ghana Health Service ERC (FWA No. 000200025) and the Kintampo Health Research Center Institutional Ethics Committee, FWA No. 00011103), Kenya (KEMRI Scientific and Ethics Review Unit, 04-10-358-4166), Zambia (University of Zambia Biomedical Research Ethics Committee, IRB00001131 of IORG0000774 and UNC Biomedical IRB 356795), India (Office of Research, Christian Medical College, Vellore, India Ethics Committee, IRB14553), India (Ethics Review Committee, Society for Applied Studies, New Delhi, SAS/ERC/ReMAPP Study/2022 Department of Health Research, EC/NEW/INST/2022/DL/0140), Pakistan (National Institutes of Health - Health Research Institute, National Bioethics Committee Ref: No.4-87/NBC-962/23/593 and Aga Khan University Ethics Review Committee, 2022-7197-21350), and the United States (Columbia University IRB IRB-AAAU7504 The George Washington University IRB NCR224396 Harvard University IRB IRB-23-1093). The rights and safety of all study participants will be protected. Written informed consent, assent and parental consent will be sought from all study participants as appropriate prior to enrollment. Site-specific unique identification numbers will be issued to participants instead of names to protect their identity. A limited data set will be stored in a secure cloud server where only trained study staff will have credentials for access. Study participants with abnormal biochemical results will be referred for further clinical assessment and management according to study-specific standard operating procedures.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.